There have been significant advancements in needle-free injection technology, which aim to increase adoption of self-injectable therapies and adherence. Patients often lack the confidence to self-inject or are put off by the complexity, impacting their ability to incorporate these therapies into their lifestyle.
Nanotechnology opens up a portal into living tissue that allows scientists to watch cancers...
There have been significant advancements in needle-...
Scientists recently demonstrated that biphasic vesicles can deliver large-molecule or macromolecule drugs into the skin. Success with biphasic vesicles offers the potential for needle-free administration of many pharmaceuticals that could previously only be administered by injection.
Capsugel’s Vcaps Plus capsules are produced without a gelling agent that can delay dissolution and lead to unwanted issues during product development.
Although drug discovery gets much of the attention in the pharmaceutical industry, stability plays an equally fundamental role. A drug must remain potent and safe long after it leaves a manufacturing facility. Ensuring this safety requires a range of technologies and applications.
Drug manufacturing processes―especially production of drugs delivered through inhalation―must have strict control over contaminate particles. Numerous methodologies allow companies to monitor these particles, the challenge is gathering the information quickly enough in order to be able to detect manufacturing problems.
Selexis SA announced that its US-based customer, Lubris LLC, has achieved over 1 g/L per liter yield in manufacturing production runs of LUB-13-04.
Quotient Clinical and Capsugel have announced a collaboration to enable the rapid development and clinical assessment of lipid-based formulations.
Ambrx Inc. said that it will receive $15 million and could receive more than $300 million from a partnership with Merck & Co. to develop drugs using its technology.
While exploratory clinical trials have been proposed for years,interest has boomed since the publication of the ICH M3 R2 guidelines in 2008.
Quotient Clinical has received approval of the final patent for its Enterion technology. This completes a portfolio of eight granted patents across North America and Europe.
Based on the recommendations and requirements of regulatory agencies, many pharmaceutical companies and contract manufacturers are developing particle characterization programs.
The FlowCAM PV Series imaging particle analysis system from Fluid Imaging Technologies automatically takes high-resolution, digital images of individual particles of encapsulated Paclitaxel.
Atomic force microscopy is part of a broad class of scanning probe microscopes that were originally developed in the 1980s. AFMs physically track samples with a microfabricated probe to generate 3D topographical images.
Almac, a provider of contract services to the pharmaceutical and biotech industries, has acquired encapsulation equipment for their North American headquarters in Souderton, Pa.
Sol-Gel Technologies Ltd. has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization of a major dermatologic drug.
Daiichi Sankyo Co. Ltd. and Terumo Corporation announced an agreement to co-develop a new vaccine for the prevention of infectious diseases, utilizing Terumo’s intradermal injection device.
This webinar discusses the methodologies used to characterize sub-visible particulates in parenterals, Dynamic Image Analysis for particulate characterization and orthogonal instrument methodologies.
The concept of an electronic pill has been around for decades. Many have imagined and even pursued a swallowed capsule with electronic function on board to measure, intervene, and/or deliver a drug while passing through the gastrointestinal tract.
Body surface area (BSA) has long been the gold standard for determining the appropriate dose of chemotherapeutic agents. Numerous studies, however, have shown that this results in large patient variability due to variations in drug biodistribution, genetic variation, metabolism, and clearance.
Advances in nanotechnology—the discovery of materials with new compositions and performance properties—as well as advances in manufacturing processes and scale are having a revolutionary impact on the diagnosis, treatment, monitoring, and prevention of disease.
New research shows how metal surfaces that lack mirror symmetry could provide a novel approach towards manufacturing pharmaceuticals.
The advent of stable isotopes have allowed the relative or even absolute quantification of proteins by mass spectrometric techniques based upon their well-characterized increase in molecular mass compared to the native protein or peptide of interest.
The Food and Drug Administration, lawmakers, and industry officials are attempting to curtail an impending crisis in the availability of critical drugs. Legislation is pending that would require pharmaceutical manufacturers to give the FDA advance notice of possible shortages.
A sister publication—R&D Magazine—will present the 49th Annual R&D 100 Awards this month. Among the top technologies and processes introduced in 2010 are many with direct applications in life sciences and drug research.
The objective of a Phase 1, first-time-in-man clinical trial is to provide information on drug pharmacokinetics and pharmacodynamics in humans and to determine the appropriate dose to be taken into further clinical studies.
Biobetter drugs offer unique opportunities and challenges. These drugs aim at similar targets and indications as existing biologic products, but provide some improvement other than price, such as efficacy, safety, or dosing regimens.